EPRSQ Projected Dividend Yield
EPIRUS Biopharmaceuticals Inc ( OTCBB : EPRSQ )EPIRUS Biopharmaceuticals is a global biopharmaceutical company focused on building a biosimilar business. Co.'s primary product candidate is BOW015 (infliximab), a monoclonal antibody against tumor necrosis factor alpha, which is used to treat inflammatory diseases. Co.'s other pipeline products, BOW050 (adalimumab), a proposed biosimilar to Humira, BOW070 (tocilizumab), a proposed biosimilar to Actemra, BOW080 (eculizumab), a proposed biosimilar to Soliris, BOW090 (ustekinumab), a proposed biosimilar to STELARA and BOW100 (golimumab), a proposed biosimilar to SIMPONI, are in preclinical development. 20 YEAR PERFORMANCE RESULTS |
EPRSQ Dividend History Detail EPRSQ Dividend News EPRSQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |